Compare abrdn Physical Palladium Shares ETF (PALL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
abrdn Physical Palladium Shares ETF vs TG Therapeutics Inc — how do they compare? abrdn Physical Palladium Shares ETF trades at $24.65, while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: TG Therapeutics Inc is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals.
| PALL | TGTX | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $37.18 | $59.06 |
52-Week Low | $20.97 | $26.94 |
Market Cap | — | $8.53B |
Enterprise Value | — | $8.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PALL, the Aberdeen Physical Palladium Shares ETF, trades at $24.43, down 3.48% over 24 hours. Technical indicators are bearish, with moving averages signaling sell pressure, while oscillators are neutral. Recent news highlights palladium's underperformance relative to other precious metals, with some analysts viewing current price weakness as a potential buying opportunity due to supply risks and industrial demand.
The outlook for PALL hinges on palladium's supply-demand dynamics and broader commodity trends. Investment opportunities exist if palladium prices rebound from support levels, but risks include continued commodity volatility and macroeconomic pressures affecting industrial demand.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
